Sagar K Chokshi1, Elena J Ladas2,3, Katherine Taromina2, Douglas McDaniel2, Diane Rooney2, Zhezhen Jin4, Wei-Chun Hsu5, Kara M Kelly2. 1. Department of Obstetrics and Gynecology, Cooper University Hospital, Camden, New Jersey. 2. Division of Pediatric Hematology, Oncology, and Stem Cell Transplant, Columbia University Medical Center, New York, New York. 3. Institute of Human Nutrition, Columbia University Medical Center, New York, New York. 4. Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York. 5. Department of Healthcare Policy and Research, Weill Cornell Medical College, Cornell University, New York, New York.
Abstract
BACKGROUND: Evidence for the application of acupuncture in pediatric oncology is limited. We investigated the acceptance of acupuncture and factors associated with its use among children and adolescents with cancer. METHODS: Ninety acupuncture-naïve children receiving cancer treatment at Columbia University Medical Center (CUMC) provided consent/assent for participation. Participants could choose to receive or refuse integrative services offered at CUMC. Symptoms were collected for a 6-month period with the Memorial Symptom Assessment Scale (MSAS). Acute and delayed adverse events among participants who received acupuncture were recorded. RESULTS: Fifty-four percent of the participants elected to receive acupuncture. In total, 252 acupuncture sessions were administered with a median of four sessions per patient (range 1-13 sessions). Pain (56%), nausea (51%), lack of energy (50%), and irritability (43%) were the most frequently reported symptoms in the whole cohort. Determinants of acupuncture use included older age and ethnicity. Acupuncture was more likely than other integrative modalities to be used for gastrointestinal and constitutional symptoms including drowsiness (odds ratio [OR], 3.34; 95% confidence interval [CI], 1.98-5.66; P < 0.0001), lack of energy (OR, 3.23; 95% CI, 1.78-5.87; P = 0.0001), and pain (OR, 2.63; 95% CI, 1.46-4.72; P = 0.001). Adverse events were reported by 3% of the participants. There was no increased incidence of adverse events in children with thrombocytopenia (P = 0.189) or neutropenia (P = 0.497). CONCLUSION: Our results highlight the potential use of acupuncture as a safe, adjunctive therapy for symptom management within existing supportive care regimens in pediatric oncology and potential areas to focus research initiatives.
BACKGROUND: Evidence for the application of acupuncture in pediatric oncology is limited. We investigated the acceptance of acupuncture and factors associated with its use among children and adolescents with cancer. METHODS: Ninety acupuncture-naïve children receiving cancer treatment at Columbia University Medical Center (CUMC) provided consent/assent for participation. Participants could choose to receive or refuse integrative services offered at CUMC. Symptoms were collected for a 6-month period with the Memorial Symptom Assessment Scale (MSAS). Acute and delayed adverse events among participants who received acupuncture were recorded. RESULTS: Fifty-four percent of the participants elected to receive acupuncture. In total, 252 acupuncture sessions were administered with a median of four sessions per patient (range 1-13 sessions). Pain (56%), nausea (51%), lack of energy (50%), and irritability (43%) were the most frequently reported symptoms in the whole cohort. Determinants of acupuncture use included older age and ethnicity. Acupuncture was more likely than other integrative modalities to be used for gastrointestinal and constitutional symptoms including drowsiness (odds ratio [OR], 3.34; 95% confidence interval [CI], 1.98-5.66; P < 0.0001), lack of energy (OR, 3.23; 95% CI, 1.78-5.87; P = 0.0001), and pain (OR, 2.63; 95% CI, 1.46-4.72; P = 0.001). Adverse events were reported by 3% of the participants. There was no increased incidence of adverse events in children with thrombocytopenia (P = 0.189) or neutropenia (P = 0.497). CONCLUSION: Our results highlight the potential use of acupuncture as a safe, adjunctive therapy for symptom management within existing supportive care regimens in pediatric oncology and potential areas to focus research initiatives.
Authors: Farah Z Zia; Oluwadamilola Olaku; Ting Bao; Ann Berger; Gary Deng; Arthur Yin Fan; Mary K Garcia; Patricia M Herman; Ted J Kaptchuk; Elena J Ladas; Helene M Langevin; Lixing Lao; Weidong Lu; Vitaly Napadow; Richard C Niemtzow; Andrew J Vickers; Xin Shelley Wang; Claudia M Witt; Jun J Mao Journal: J Natl Cancer Inst Monogr Date: 2017-11-01
Authors: Hyeongjun Yun; Sally A D Romero; Benjamin Record; Julia Kearney; Nirupa Jaya Raghunathan; Stephen Sands; Jun J Mao Journal: Pediatr Blood Cancer Date: 2019-01-31 Impact factor: 3.167
Authors: Andrea L Radossi; Katherine Taromina; Stacey Marjerrison; Caroline J Diorio; Raquel Similio; Festus Njuguna; Glenn M Afungchwi; Elena J Ladas Journal: Support Care Cancer Date: 2017-10-13 Impact factor: 3.603
Authors: Dana C Mora; Grete Overvåg; Miek C Jong; Agnete E Kristoffersen; Debbie C Stavleu; Jianping Liu; Trine Stub Journal: BMC Complement Med Ther Date: 2022-04-02